Forecasts of explosive AI progress predict that what researchers call recursive self-improvement is on the horizon. But a new study suggests that it might take a while for us to get there. The ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Bob Brooks promises ‘change’ in his bid for Congress. Can he win over Lehigh Valley voters with blue collar bona fides? Bob Brooks has worked many jobs throughout his life: newspaper deliverer, truck ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.
Recursion Pharmaceuticals insiders completed 6 transactions totaling $589,430.56. Activity included 2 tax-related stock dispositions, 2 open market sales, and 2 stock awards (non-cash). View more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results